

June 22, 2022

Iron Deficiency Leading to Severe Morbidity;

Presented by Mark Tomlinson, MD

Confidential and Privileged: This document and the peer review data contained herein are privileged and protected by ORS 41.675 & 41.685, the Federal Health Care Quality Improvement Act of 1986 and other applicable law.

Conflicts of Interest

I have no financial conflicts




Objectives

- Understand the link between iron deficiency, anemia, and severe maternal morbidity
- Highlight disparities
- Discuss potential approaches to anemia prevention

Anemia in Pregnancy is Clinically Important

- Very common and significance often under emphasized
- More common in women than men
- More common in pregnant than nonpregnant women
- Iron deficiency anemia is most common and easy to treat
- Disparities exist
- Importance evidenced by:
 - Routine screening twice in pregnancy
 - Prenatal vitamins routinely contain iron
 - Supplemental additional iron is often recommended





Neonatal Outcomes Associated with Maternal Iron Deficiency

- Anemia
 - Preterm delivery
 - SGA
 - Perinatal mortality
- Iron deficiency
 - Lower cord blood ferritin
 - Neurodevelopmental & behavioral abnormalities in childhood

Anemia in Pregnancy

	Definition Hgb(Hct)	Prevalence (%)	Prevalence of Hgb<10 g/dl (%)
1 st trimester	<11.0 (33.0)	1.8	
2 nd trimester	<10.5 (32.5)	8.2	
3 rd trimester	<11.0 (33.0)	27.4	
Non-Hispanic white	Historically definition varied		1.8%
Non-Hispanic Black	by race*		3.5%

ACOG Practice Bulletin #233, 2021 *ACOG Practice Bulletin #95, 2008

Anemia between 2-16 weeks and SMM

Hgb Level (g/dl) (n=737,393)	SMM (%)	SMM (RR)	Transfusion (%)	Transfusion (RR)
12.5-12.9	1.7	1.00	0.7	1.00
12.0-12.4	1.8	1.07	0.8	1.1
10.5-10.9	2.4	1.31	1.4	1.9
<9.0	8.2	4.53	8.3	11.8
13.0 - >15.0	1.7-21	NS	0.6-0.7	0.8-0.9

Ray, BJOG 2020


PROVIDENCE

Disparities in Anemia and SMM

Race	Prevalence (%)	aRR of SMM with Anemia	Adjusted SMM Pop Attributable Risk (%)
White	9.6	1.00	14.7
Black	21.5	1.27	20.9
Hispanic	12.6	1.17	20.9
Asian	10.6	1.33	11.3
ALAN	14.1	1.53	16.7
Pacific Islander	18.2	1.68	16.4
Multiple Races	14.0	1.10	21.4

Igninosa, OB & Gyn 2023 + PROVIDENCE

Path from Anemia to Severe Maternal Morbidity





Ferritin

- Bone marrow biopsy is only direct way to measure iron stores
- Ferritin most sensitive, specific and widely used noninvasive measure of iron deficiency
- Increased in
 - Infection/inflammation
 - Elevated in hemoglobinopathies or hemolytic anemia
 - Can help determine need for supplementation
 - Liver disease



Zuguo, Lancet 2021 + PROVIDENCE

Iron Deficiency in Pregnancy

	Definition (mg/dl) Ferritin Level	Prevalence* (%)
1 st trimester		6.9
2 nd trimester	<10 (ACOG 2008) <30 (ACOG 2021)	14.3
3 rd trimester		29.5

*Prevalence based on limited data USPSTF - "I" recommendation (2015) – evidence insufficient to assess balance of benefits and harms (Update pending)

Risk factors

- Parity >2
- Non-Hispanic black and Mexican American

ACOG Practice Bulletin #233, 2021

1st Trimester Screening for Anemia at Delivery

	Predelivery anemia		
Parameter	Sensitivity	Specificity	ROC-AUC
Ferritin <30	0.71	0.72	0.78
Hgb < 11.0	0.27	0.98	0.60

Crispin, Transfusion and Apheresis Science 2019

What to do?

- Evidence to support screening for iron deficiency is very limited
- Mild anemia (hgb > 10 & <11 g/dl) or normal Hgb at lower limits of normal with a normal or low MCV
 - Either check ferritin or provide a trial of supplemental iron
- Those with macrocytic anemia, very low MCV, moderate (7.0-9.9 g/dl) or severe anemia should be further evaluated
- Oral iron is treatment of choice
 - Every other day therapy is as effective as daily iron over the long term with fewer side effects
- IV iron is indicated for those that fail oral therapy (compliance challenges, poor absorption, inability to tolerate) or late in pregnancy when there isn't time for oral therapy to be effective

PROVIDENCE

Summary

- Anemia disparities, identification, and management are garnering increased attention
- Screening for iron deficiency (not just anemia) has the potential to improve outcomes



Mark.Tomlinson@providence.org

